Bragar Eagel & Squire, P.C. Is Investigating Liquidia, Napco, and Franklin and Encourages Investors to Contact the Firm
30. September 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Liquidia Corporation...
Bragar Eagel & Squire, P.C. Is Investigating Paragon 28, Centuri, Liquidia, and Elastic and Encourages Investors to Contact the Firm
16. September 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Paragon 28, Inc. (NYSE:...
LIQUIDIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm
27. August 2024 22:00 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Liquidia Corporation...
Liquidia Technologies Reports Positive Interim LIQ861 Safety Data on 109 Patients from Pivotal INSPIRE Trial
07. Januar 2019 07:00 ET
|
Liquidia Technologies, Inc.
LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDANDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2019 ...
Liquidia Technologies Provides Leadership Update
27. November 2018 16:45 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Technologies Recipient of Best-in-Class Public Offering Award at Southeast BIO
14. November 2018 16:30 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Technologies to Present LIQ865 Phase 1a Data at ASRA’s 17th Annual Pain Medicine Meeting
14. November 2018 08:00 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Technologies to Present at Jefferies London Healthcare Conference
09. November 2018 08:00 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and...
Liquidia Technologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
31. Oktober 2018 07:00 ET
|
Liquidia Technologies, Inc.
Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trialTwo-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019Dr. Stephen Bloch appointed as...
Liquidia Technologies to Provide Third Quarter 2018 Corporate Update on October 31, 2018
23. Oktober 2018 08:00 ET
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development...